Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Clinical Trial ID NCT00323882

PubWeight™ 13.96‹?›

🔗 Visit the page for NCT00323882

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013 2.35
2 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
3 Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014 1.29
4 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
5 Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 2012 0.89
6 Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res 2016 0.88
7 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
8 Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med 2016 0.87
9 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
10 New advances in targeted gastric cancer treatment. World J Gastroenterol 2016 0.81
11 Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer 2014 0.80
12 Ipilimumab. Drugs R D 2010 0.79
13 Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med 2013 0.75
14 How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist 2016 0.75
Next 100